SG11202001368SA - Antigen-binding proteins tatrgeting shared antigens - Google Patents

Antigen-binding proteins tatrgeting shared antigens

Info

Publication number
SG11202001368SA
SG11202001368SA SG11202001368SA SG11202001368SA SG11202001368SA SG 11202001368S A SG11202001368S A SG 11202001368SA SG 11202001368S A SG11202001368S A SG 11202001368SA SG 11202001368S A SG11202001368S A SG 11202001368SA SG 11202001368S A SG11202001368S A SG 11202001368SA
Authority
SG
Singapore
Prior art keywords
tatrgeting
antigen
binding proteins
shared antigens
antigens
Prior art date
Application number
SG11202001368SA
Other languages
English (en)
Inventor
Karin Jooss
Wade Blair
Brendan Bulik-Sullivan
Jennifer Busby
Michele Anne Busby
Mojca Skoberne
Roman Yelensky
Joshua Francis
Gijsbert Grotenbreg
Original Assignee
Gritstone Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gritstone Oncology Inc filed Critical Gritstone Oncology Inc
Publication of SG11202001368SA publication Critical patent/SG11202001368SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202001368SA 2017-08-18 2018-08-17 Antigen-binding proteins tatrgeting shared antigens SG11202001368SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762547146P 2017-08-18 2017-08-18
US201762581368P 2017-11-03 2017-11-03
PCT/US2018/046997 WO2019036688A1 (en) 2017-08-18 2018-08-17 ANTIGEN BINDING PROTEINS TARGETING SHARED ANTIGENS

Publications (1)

Publication Number Publication Date
SG11202001368SA true SG11202001368SA (en) 2020-03-30

Family

ID=65362959

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202001368SA SG11202001368SA (en) 2017-08-18 2018-08-17 Antigen-binding proteins tatrgeting shared antigens

Country Status (12)

Country Link
US (2) US20210147550A1 (enExample)
EP (1) EP3668539A4 (enExample)
JP (1) JP2021500852A (enExample)
KR (2) KR20250040097A (enExample)
CN (1) CN111328288B (enExample)
AU (1) AU2018318303A1 (enExample)
CA (1) CA3072816A1 (enExample)
IL (1) IL272466A (enExample)
MX (2) MX2020001879A (enExample)
SG (1) SG11202001368SA (enExample)
WO (1) WO2019036688A1 (enExample)
ZA (1) ZA202001285B (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202102698VA (en) 2014-12-23 2021-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
US9422547B1 (en) 2015-06-09 2016-08-23 Gigagen, Inc. Recombinant fusion proteins and libraries from immune cell repertoires
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
CA3086923A1 (en) * 2017-12-28 2019-07-04 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared antigens
WO2019204683A1 (en) * 2018-04-19 2019-10-24 Board Of Regents, The University Of Texas System T cell receptors with mage-b2 specificity and uses thereof
EP3836958A1 (en) * 2018-08-17 2021-06-23 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared antigens
CN111138522B (zh) * 2018-11-06 2023-01-24 香雪生命科学技术（广东）有限公司 衍生自afp的肿瘤抗原短肽
CN111138521B (zh) * 2018-11-06 2022-10-28 香雪生命科学技术（广东）有限公司 源自于afp抗原的短肽
EP3927727A1 (en) * 2019-02-20 2021-12-29 Fred Hutchinson Cancer Research Center Binding proteins specific for ras neoantigens and uses thereof
WO2020191365A1 (en) * 2019-03-21 2020-09-24 Gigamune, Inc. Engineered cells expressing anti-viral t cell receptors and methods of use thereof
EP3714941A1 (en) 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
US20200318068A1 (en) * 2019-04-04 2020-10-08 Immatics US, Inc. Use of retinoic acid in t-cell manufacturing
CA3135850A1 (en) 2019-04-05 2020-10-08 Rootpath Genomics, Inc. Compositions and methods for t-cell receptor gene assembly
US20220213167A1 (en) * 2019-05-03 2022-07-07 Gigamune, Inc. Engineered cells expressing anti-tumor t cell receptors and methods of use thereof
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
EP3760217A1 (en) * 2019-07-01 2021-01-06 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Cd5 specific t cell receptor cell or gene therapy
CN114375303B (zh) * 2019-07-09 2025-04-22 基因医疗免疫疗法有限责任公司 Magea10特异性t细胞受体及其用途
KR20220047277A (ko) 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
CN112300261B (zh) * 2019-07-23 2023-03-17 香雪生命科学技术（广东）有限公司 一种衍生自afp的肿瘤抗原短肽
WO2021034890A1 (en) * 2019-08-19 2021-02-25 Pandion Therapeutics, Inc. Targeted immunotolerance with a pd-1 agonist
WO2021048381A1 (en) * 2019-09-13 2021-03-18 Evaxion Biotech Aps Method for identifying stable mhc binding peptides using mass spectrometry
EP4045066A4 (en) * 2019-10-18 2024-03-20 Board of Regents, The University of Texas System HLA-RESTRICTED VCX/Y PEPTIDES AND T-CELL RECEPTORS AND THEIR USE
WO2021092094A1 (en) * 2019-11-04 2021-05-14 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared neoantigens
JP2023502625A (ja) * 2019-11-15 2023-01-25 グリットストーン バイオ インコーポレイテッド 共有新抗原を標的にする抗原結合タンパク質
CN112898399A (zh) * 2019-12-03 2021-06-04 香雪生命科学技术（广东）有限公司 源自于afp抗原的短肽
CN115960205A (zh) * 2019-12-13 2023-04-14 南京大户生物科技有限公司 原发性肝癌相关抗原的胸腺依赖性淋巴细胞抗原表位肽及其应用
CN113072636B (zh) * 2020-01-06 2024-05-28 香雪生命科学技术（广东）有限公司 一种识别afp的t细胞受体及其编码序列
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
CN113321725B (zh) * 2020-02-28 2024-06-11 香雪生命科学技术（广东）有限公司 一种识别afp的t细胞受体
CN113321727B (zh) * 2020-02-28 2024-04-09 香雪生命科学技术（广东）有限公司 一种识别afp抗原短肽的t细胞受体及其编码序列
JP2023517889A (ja) * 2020-03-10 2023-04-27 マサチューセッツ インスティテュート オブ テクノロジー ＮＰＭ１ｃ陽性がんの免疫療法のための組成物および方法
CN113493505A (zh) * 2020-03-20 2021-10-12 香雪生命科学技术（广东）有限公司 识别afp抗原的高亲和力tcr
JP7785696B2 (ja) * 2020-05-18 2025-12-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 操作されたｔ細胞受容体および使用の方法
CA3183756A1 (en) * 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
US20230227526A1 (en) * 2020-06-09 2023-07-20 Board Of Regents, The University Of Texas System Engineered t cell receptors and methods of use
CN114730938A (zh) 2020-07-08 2022-07-08 株式会社Lg新能源 电池组和包括该电池组的车辆
EP4188962A4 (en) * 2020-07-29 2025-01-01 Gritstone bio, Inc. MANIPULATED MULTI-SPECIFIC ANTIBODIES AND RELATED METHODS OF USE AND PRODUCTION
WO2022051449A2 (en) * 2020-09-04 2022-03-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing r273c or y220c mutations in p53
CA3193172A1 (en) * 2020-09-24 2022-03-31 Kathrin DAVARI Mage-a3 specific t cell receptors and their use
WO2022063966A1 (en) * 2020-09-24 2022-03-31 Medigene Immunotherapies Gmbh Prame specific t-cell receptors and uses thereof
WO2022087380A1 (en) * 2020-10-23 2022-04-28 Rootpath Genomics, Inc. Compositions and methods for t-cell receptor identification
EP4570256A3 (en) * 2020-11-05 2025-09-24 Board of Regents, The University of Texas System Engineered t cell receptors targeting egfr antigens and methods of use
EP4277925A4 (en) * 2021-01-14 2025-06-11 Gritstone bio, Inc. Multispecific antibodies and methods of use
AU2022207422A1 (en) 2021-01-14 2023-07-27 Gilead Sciences, Inc. Hiv vaccines and methods of using
EP4294831A1 (en) * 2021-02-16 2023-12-27 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class i-restricted t cell receptors against cd22
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
WO2022190009A1 (en) 2021-03-09 2022-09-15 Cdr-Life Ag Mage-a4 peptide-mhc antigen binding proteins
US20240293459A1 (en) * 2021-03-29 2024-09-05 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting sars-cov-2 antigens and methods of use
WO2022216574A1 (en) * 2021-04-05 2022-10-13 Janssen Biotech, Inc. Calr and jak2 t-cell receptors
JP2024518302A (ja) 2021-04-29 2024-05-01 イェダ リサーチ アンド デベロップメント カンパニー リミテッド Ｒａｓ誘導性再発性ネオアンチゲンに対するｔ細胞受容体およびそれらを同定するための方法
EP4091627A1 (en) * 2021-05-21 2022-11-23 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for magea4-derived epitopes
EP4347639A4 (en) * 2021-05-25 2025-08-06 Memorial Sloan Kettering Cancer Center T CELL RECEPTORS TARGETING RAS MUTATIONS AND THEIR USES
JP2024530059A (ja) * 2021-08-06 2024-08-14 アンヤディ リミテッド ライアビリティ カンパニー 個別化されたがん免疫療法を創出するためのプロセス
WO2023050063A1 (zh) * 2021-09-28 2023-04-06 溧阳瑅赛生物医药有限公司 一种识别hla-a*02:01/e629-38的tcr及其应用
CA3236237A1 (en) * 2021-10-25 2023-05-04 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use
US20240415886A1 (en) * 2021-10-29 2024-12-19 Yafei Hou T cell receptor recognizing r175h mutation in p53 and its application
EP4472742A1 (en) * 2022-02-03 2024-12-11 University College Cardiff Consultants Limited Novel t-cell receptor
CA3244259A1 (en) * 2022-02-23 2023-08-31 Aloe Therapeutics Inc Compositions and methods for modulating the immune system
NL2031118B1 (en) * 2022-03-01 2023-09-07 Academisch Ziekenhuis Leiden T cell receptors directed against transcription factor wt1 and uses thereof
CN116836261A (zh) * 2022-03-24 2023-10-03 香雪生命科学技术（广东）有限公司 一种识别mage-a4抗原的高亲和力tcr及其序列和应用
CN117264043B (zh) * 2022-06-14 2024-05-10 上海镔铁生物科技有限责任公司 靶向kras g12v突变多肽的t细胞受体及其用途
US12161673B2 (en) 2022-09-14 2024-12-10 Cdr-Life Ag MAGE-A4 peptide dual T cell engagers
AU2023241307B2 (en) * 2022-10-05 2024-10-31 Tscan Therapeutics, Inc. Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
CN116158405B (zh) * 2023-01-30 2024-04-26 西北农林科技大学 一种提高奶山羊后代母羔率的方法
WO2025064738A1 (en) * 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2025093596A2 (en) * 2023-10-30 2025-05-08 T-Knife Gmbh Antigen recognizing construct capable of binding to a preferentially expressed antigen in melanoma (prame) peptide and a t cell receptor (tcr) having antigenic specificity for prame as well as corresponding nucleic acid sequence, vector, host cell, pharmaceutical composition and kit
CN118256604B (zh) * 2024-04-16 2024-11-19 华中科技大学 一种利用人工抗原呈递细胞进行免疫原性肿瘤新抗原筛选与鉴定方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
AU2003216341A1 (en) * 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
CA2742969A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
SI3392270T1 (sl) * 2011-09-15 2020-12-31 The United States Of America, As Represented By The Secretary Department Of Health And Human Services T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni MAGE
WO2013130814A1 (en) * 2012-02-29 2013-09-06 Ambrx, Inc. Novel prodrug containing molecule compostions and their uses
TWI702229B (zh) * 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
TW201702272A (zh) * 2015-05-22 2017-01-16 美國紀念斯隆 凱特琳癌症中心 Ｐｒａｍｅ肽專一性類ｔ細胞受體抗體
GB201520559D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
US11505599B2 (en) * 2016-01-14 2022-11-22 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for Foxp3-derived peptides

Also Published As

Publication number Publication date
CN111328288A (zh) 2020-06-23
JP2021500852A (ja) 2021-01-14
AU2018318303A1 (en) 2020-04-09
MX2025011582A (es) 2025-11-03
KR20250040097A (ko) 2025-03-21
MX2020001879A (es) 2020-07-29
WO2019036688A1 (en) 2019-02-21
EP3668539A4 (en) 2021-08-18
EP3668539A1 (en) 2020-06-24
US20230382997A1 (en) 2023-11-30
CN111328288B (zh) 2025-11-07
US20210147550A1 (en) 2021-05-20
KR20200084320A (ko) 2020-07-10
CA3072816A1 (en) 2019-02-21
ZA202001285B (en) 2021-08-25
IL272466A (en) 2020-03-31

Similar Documents

Publication Publication Date Title
SG11202001368SA (en) Antigen-binding proteins tatrgeting shared antigens
IL275547A (en) Antigen-binding proteins target co-antigens
IL279321A (en) Anti-SIRPalpha antibody
IL280780A (en) Anti-TIGIT antibodies
IL267797B1 (en) Anti-gpc3 antibody
IL280013A (en) Anti-IL36R antibodies
ZA201900353B (en) Anti-pd-l1 antibodies
IL262295A (en) Antibodies against pd-l1
IL279352A (en) IL-11RA antibodies
SG10201603721TA (en) Anti-CTLA-4 Antibodies
IL278010A (en) Antibodies to galectin 10
ZA201807167B (en) Humanized anti-il-1r3 antibodies
GB201817172D0 (en) Antibody
GB202110263D0 (en) Anti-btla antibodies
IL277030A (en) Antibodies
ZA202101177B (en) Anti-btla antibody
IL273529A (en) Anti-PACAP antibody
GB201811368D0 (en) Antibody
IL323170A (en) Antibodies against KLRG1
GB201806084D0 (en) Antibodies
GB201511196D0 (en) Monoclonal antibodies
GB201819952D0 (en) Antibodies
GB201817309D0 (en) Antibodies
GB201817313D0 (en) Antibodies
GB201817311D0 (en) Antibodies